NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN
Post# of 110
(Total Views: 90)
Posted On: 02/02/2024 3:32:52 PM
NetworkNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies, which have shown that the surfaces of the drug candidate’s nanocrystals catalyze the rapid oxidation of NADH to NAD+, increasing the intracellular availability of both NAD+ and ATP. NAD+ supports the synthesis of ATP, the universal energy-containing molecule that powers most cellular functions, including brain function. The results of the REPAIR-PD and REPAIR-MS trials, which showed that treatment with CNM-Au8 resulted in a statistically significant (p < 0.05) 10.4% increase in the brain NAD+/NADH ratio, were described in a peer-review article published in the Journal of Nanobiotechnology. “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant. Other groups have shown significant deficits in brain energy metabolites associated with neurodegenerative disease,” a recent article quotes Dr. Benjamin Greenberg, Head of Medical at Clene, as saying. “Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies, which have shown that the surfaces of the drug candidate’s nanocrystals catalyze the rapid oxidation of NADH to NAD+, increasing the intracellular availability of both NAD+ and ATP. NAD+ supports the synthesis of ATP, the universal energy-containing molecule that powers most cellular functions, including brain function. The results of the REPAIR-PD and REPAIR-MS trials, which showed that treatment with CNM-Au8 resulted in a statistically significant (p < 0.05) 10.4% increase in the brain NAD+/NADH ratio, were described in a peer-review article published in the Journal of Nanobiotechnology. “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant. Other groups have shown significant deficits in brain energy metabolites associated with neurodegenerative disease,” a recent article quotes Dr. Benjamin Greenberg, Head of Medical at Clene, as saying. “Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Clene Inc. (CLNN) Stock Research Links
Scroll down for more posts ▼